Fig. 7

Co-administration of isovitexin/thiostrepton and MnSOD knockdown cooperatively suppress xenograft tumor growth of HCSLCs from MHCC97H cells in nude mice. a Xenograft tumors were photographed after treatment with vehicle, 10 mg/kg isovitexin or 5 mg/kg thiostrepton, intratumoral injection of adenovirus expressing MnSOD shRNA (once a week), or combination of isovitexin/thiostrepton plus adenovirus for 21 days in nude mice. b Tumor volumes in the vehicle control, isovitexin, thiostrepton, MnSOD shRNA, and combination treatment groups. Data are mean ± SD (n = 6); P < 0.05 indicated statistical significance. ^*Vehicle control. ^#Combination treatment group. c Xenograft tumor weights in the vehicle control, isovitexin, thiostrepton, MnSOD shRNA, and combination treatment groups. Data are mean ± SD (n = 6); P < 0.05 indicated statistical significance. ^*Vehicle control. ^#Combination treatment group. d Upper panel, H&E staining of xenograft tumors in the vehicle control, isovitexin, thiostrepton, MnSOD shRNA and combination treatment groups; middle panel, representative immunohistochemical data for MnSOD in the vehicle control, isovitexin, thiostrepton, MnSOD shRNA and combination treatment groups (magnification, × 400); lower panel, representative immunohistochemical data for FoxM1 in the vehicle control, isovitexin, thiostrepton, MnSOD shRNA and combination treatment groups (magnification, × 400)